checkedPsychopharmacology and Psychiatry Updates2026-11-08last verified 2026-11-08

did nearly two-thirds of patients in the catatonia review have psychotic disorders?

verdict: misattributed
a real number attached to the wrong thing
“the authors report that nearly two-thirds of patients in the review had psychotic disorders.”

a guest, Dr. Scott Beach (psychiatrist presenting the review) said on Psychopharmacology and Psychiatry Updates, 2026-11-08, at 06:05. hear it in context → the speaker cited: a recent systematic review in European Psychiatry.

the episode: Catatonia: Should Antipsychotics Always Be Avoided? (at 06:05). we link the show's own page; we do not re-host audio.

first, the part that holds

the number is real and the speaker reported it correctly. the european psychiatry systematic review of antipsychotics in catatonia says psychotic disorders were the most common underlying cause, at 62.9% in its results section and 65.8% in its abstract. "nearly two-thirds" is a fair reading of either figure.

what we found when we went and looked

we read the review the speaker appears to be describing: a systematic review of antipsychotic use in catatonia, published in european psychiatry (vol. 68, published online march 2025). it covered 79 articles and counted 175 antipsychotic trials in 110 patients. the results section says "psychotic disorders were the most common etiology (62.9%) with 84 antipsychotic trials involving patients suffering from schizophrenia (48.0%), 5 schizoaffective patients (2.9%), and 26 other psychotic patients (14.9%)." so the two-thirds figure is a share of treatment trials, not of patients. the review says it gives no patient-level breakdown of diagnoses, and because some patients had several trials, the share of the 110 patients who had a psychotic disorder can't be worked out from what was published.

assertion by assertion

assertionverdictwhat the record says
the review's authors report that psychotic disorders made up nearly two-thirds of casesconfirmedthe results give 62.9% and the abstract gives 65.8% as the share for psychotic disorders, the most common underlying cause. both round to nearly two-thirds. the figures don't quite agree with each other: the results count 84 + 5 + 26 = 115 of 175 trials, which works out to 65.7%, not the 62.9% printed in the same sentence. [1][2]
the two-thirds share is of patients in the reviewmisattributedthe percentages are counted over 175 antipsychotic trials, not the 110 patients. a patient who tried several antipsychotics is counted once per trial. the authors say there is no patient-level diagnosis table, so the share of patients with a psychotic disorder isn't reported and can't be calculated from the paper. [1][2]
the source is a recent systematic review in european psychiatryconfirmedit is a prisma-guided systematic review in european psychiatry, volume 68, issue 1, doi 10.1192/j.eurpsy.2025.9, published online 24 march 2025. that is about 20 months before the episode aired. we matched it on topic and the two-thirds figure; the episode did not name a title we could check. [1]
popular framing: about two-thirds of people with catatonia have a psychotic disordermisattributedthe review only included catatonic episodes that were treated with antipsychotics, a group that will naturally lean toward psychotic disorders. nearly all of its data come from case reports. it describes who was in this particular literature. it is not a prevalence estimate for the causes of catatonia in general. [2]

both directions

for the speaker: the review does report that psychotic disorders were the leading cause, at about two-thirds: 62.9% in the results and 65.8% in the abstract. schizophrenia alone made up 48.0% of trials. mood disorders came to 16.0% (bipolar disorder 9.1%, major depressive disorder 6.9%) and general medical conditions to 6.9%. so the speaker got the size and the ranking right.

against: the paper counts antipsychotic trials, not patients: 175 trials in 110 patients. the speaker said "patients," and the paper doesn't support that denominator. the paper also isn't internally consistent: its own counts give 65.7%, but the results print 62.9% and the abstract 65.8%. and because the review only included antipsychotic-treated episodes, its mix of diagnoses doesn't tell you how common psychotic disorders are among people with catatonia in general.

what this cannot say

nearly all of the review's data come from case reports, which the authors say are prone to publication bias, recall bias and overinterpretation. the patient-level share of psychotic disorders isn't reported, so we can't say whether it is higher or lower than two-thirds. on our side: the episode named only "a recent systematic review in european psychiatry," so we matched the review by topic and figure, and we may have the wrong paper. we read the journal's article page and full-text reader. we did not see the supplementary tables.

sources, each one fetched and read

  1. The use of antipsychotics in the treatment of catatonia: a systematic review. European Psychiatry, vol. 68, issue 1, 2025. doi:10.1192/j.eurpsy.2025.9 What we read there: abstract: "we identified 175 antipsychotic trials (in 110 patients)... Psychotic disorders were the most common underlying etiology (65.8%)." antipsychotic use was judged beneficial in 60.0% of trials, neutral in 29.1% and harmful in 10.9%. Fetched 2026-11-08 (HTTP 200). https://www.cambridge.org/core/journals/european-psychiatry/article/use-of-antipsychotics-in-the-treatment-of-catatonia-a-systematic-review/332FE3F1201E16C3F67ECBB059DA85DD
  2. same article, Cambridge Core full-text reader, European Psychiatry 2025 What we read there: "Psychotic disorders were the most common etiology (62.9%) with 84 antipsychotic trials involving patients suffering from schizophrenia (48.0%), 5 schizoaffective patients (2.9%), and 26 other psychotic patients (14.9%)." also: "Publications that did not report detailed patient-level data were not included" and "Almost all of the included data come from case reports." Fetched 2026-11-08 (HTTP 200). https://www.cambridge.org/core/product/332FE3F1201E16C3F67ECBB059DA85DD/core-reader

speakers are described by role, not named. one sentence is quoted under fair use, with attribution and a link to the original at the timestamp; we do not re-host audio or video. nothing on this page is a reason to start, stop or change a medication. if you have the file behind anything marked unverifiable, the research board is where people can answer. adam